Descripción de la empresa
AVITA Medical, Inc. operates as a therapeutic acute wound care company with a geographic footprint extending across the United States, Japan, the European Union, Australia, and the United Kingdom. The firm specializes in medical devices, specifically focusing on the RECELL System, which is a cell harvesting device utilized for the treatment of thermal burns. Within the broader Healthcare sector, the company functions within the Medical Devices industry, providing specialized solutions for acute wound management that distinguish it from general healthcare providers. AVITA Medical, Inc. currently holds a market capitalization of $118.55M and generates $71.61M in annual revenue while employing a workforce of 226 individuals. These valuation and revenue figures indicate that the company operates on a mid-cap scale with a revenue base that supports its specialized product portfolio but remains subject to the financial constraints typical of a company in a growth-oriented yet loss-making phase. The market cap reflects investor sentiment regarding the company's potential to capture market share in the acute wound care segment, while the employee count suggests an operational structure designed to support global distribution and technical service for its lead product.
Salud financiera
The company reported revenue of $71.61M over the trailing twelve months, yet recorded a net income of $-48,587,000, highlighting a significant divergence between top-line sales and bottom-line profitability. The EBITDA for the period stood at $-40,240,000, which, when compared to the net income loss, reveals that the company incurs substantial costs related to interest expense or taxes that further erode operating earnings. The free cash flow generated was $-18,330,750, indicating that the company is currently burning cash rather than generating liquidity, which limits its financial flexibility for capital expenditures or strategic acquisitions without external financing. Analysis of the three primary margins shows a gross margin of 82.1%, suggesting high efficiency in production costs relative to sales, while the operating margin is -59.1% and the profit margin is -67.8%, indicating that heavy operating expenses are compressing overall profitability. On the balance sheet, the company holds $18.18M in cash against $46.05M in debt, and while the debt-to-equity ratio is listed as N/A, the leverage is significant given the negative equity position implied by the valuation metrics. The current ratio stands at 0.57, which signals that current assets are insufficient to cover current liabilities, pointing to potential short-term liquidity pressures. Return on Equity is N/A due to the negative equity base, and the Return on Assets is -39.1%, revealing that management is currently destroying value relative to the asset base employed in operations.
Evaluación de valoración
The trailing P/E ratio is listed as N/A because the company has not generated positive earnings over the trailing twelve months, while the forward P/E is -19.32, a figure that implies negative expected earnings in the near future. The price-to-book ratio is -7.10, a negative multiple that indicates the market values the company significantly below its book value, reflecting investor concerns about the quality of assets or the ability to generate future cash flows. The price-to-sales ratio is 1.66, and the EV/EBITDA stands at -3.64; these alternative metrics suggest that the market is pricing the stock based on revenue multiples rather than earnings, which is common for companies in early growth stages or those facing temporary profitability challenges. The stock has traded between a 52-week low of $3.22 and a 52-week high of $10.29, meaning the current price sits at a level that reflects high volatility and uncertainty regarding the path to profitability. The beta value is 1.89, which indicates that the stock's price volatility is substantially higher than the broader market, making it a high-risk component of a diversified portfolio. This elevated beta suggests that price movements will be amplified by market swings, a characteristic often seen in small-cap biotech or medical device companies with limited revenue streams.
Growth & Income
The revenue growth year-over-year is -4.3%, and the earnings growth year-over-year is N/A due to the absence of positive historical earnings for comparison. The negative revenue growth rate indicates that the company is contracting its top line, which poses a challenge to achieving the scale necessary to cover its fixed costs and reach profitability. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, meaning it reinvests all available resources into operations rather than returning capital to shareholders. The overall growth and income profile is characterized by revenue contraction and a complete lack of dividend income, reflecting a strategy focused on operational survival and product development rather than shareholder returns. The absence of dividend payments combined with negative earnings growth underscores the company's current phase of capital allocation, where internal cash generation is insufficient to fund operations without external debt or equity financing.